Objective We aimed to critically evaluate the cost benefits of a clinically proven non-commercial, aseptic closed VTF system to other commonly used open/hybrid VTF devices, and discuss the importance of cost-savings in today’s assisted reproductive technology (ART) industry. Design Theoretical modeling of 500 PGS/VTF-all cycles was prospectively evaluated to assess costs comparing the use of a non-commercial microSecure (µS) VTF device system to three common commercial systems: Cryolock (CL), Rapid-i (R-i) and High Security Straws (HSV) VTF devices. In the analysis, we assumed a mean of 5 blastocysts biopsied per cycle yielding 2 euploid embryos for 2 vitrified ET (VFET) cycles. Media and solution costs were excluded. Materials and methods Costs were calculated based on protocol and prices used within our laboratory network. The CL VTF procedure used: 5 x CLs ($15.00 × 5 = $75.00), 2 x Stripper tips ($6.17 × 2 = $12.34) and 2 × 4 well dishes ($2.42 × 2 = $4.84). Conversely, the µS-VTF protocol used: 5 x CBS semen/embryo straws ($2.75 × 5 = $13.75), flexipettes ($4.00 × 6 = $24.00) and 2 × 100mm dishes ($0.25 × 2 = $0.50). In considering the potential use of R-i or HSV devices commonly used in the industry, we simply replaced the CL model with higher device costs ($22.50 × 5 = $112.50). Warming costs are particularly low with the µS-VTF technique as the embryo already resides in a flexipette, requiring only: 60 mm warming dishes ($0.25 × 2 = $0.50) and 6-well dilution dishes ($1.40 × 2 = $2.80). Cryolock warming costs required: Stripper tips ($6.17 × 8 = $49.36), organ well dishes ($1.70 × 2 = $3.40), and 4-well dishes ($2.42 × 2 = $4.84). Results The application of the µS-VTF offers significant cost-savings compared to our commercial use of CL devices (see Table). Based on our theoretical model (500 cycles), a total savings of up to $64,275 can be achieved depending on the commercial VTF device used. Conclusion Although VTF expenses represent a fraction ( Disclosures MCS developed µS-VTF without commercial interests. Funding None.